BetterLife Pharma Inc.
BETR
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.44% | -1.29% | 206.99% | 120.76% | -87.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.69% | 6.69% | 195.26% | 7.22% | -84.24% |
| Operating Income | -1.69% | -6.69% | -195.26% | -7.22% | 84.24% |
| Income Before Tax | 399.11% | -37.31% | -112.26% | -19.44% | 95.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 399.11% | -37.31% | -112.26% | -19.44% | 95.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -322.96% | 3.23% | -82.72% | -1,129.16% | -95.55% |
| Net Income | 406.18% | -37.57% | -422.66% | -106.64% | 95.52% |
| EBIT | -1.69% | -6.69% | -195.26% | -7.22% | 84.24% |
| EBITDA | -- | -- | -- | -7.26% | 84.33% |
| EPS Basic | 361.54% | -24.29% | -359.26% | -61.54% | 96.52% |
| Normalized Basic EPS | 112.50% | -22.73% | -7,800.00% | -130.77% | 96.19% |
| EPS Diluted | 330.77% | -16.00% | -98.65% | -61.54% | 96.54% |
| Normalized Diluted EPS | 112.50% | -22.73% | -7,800.00% | -130.77% | 96.19% |
| Average Basic Shares Outstanding | 14.73% | 10.31% | 15.89% | 28.28% | 31.31% |
| Average Diluted Shares Outstanding | 30.05% | 10.31% | 15.89% | 28.28% | 31.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
